SGLT-2-Inhibitoren aus der Sicht des Kardiologen

Ther Umsch. 2017;74(8):462-464. doi: 10.1024/0040-5930/a000941.

[Article in German]

Author

Otmar Pfister¹

Affiliation

¹ 1 Klinik für Kardiologie, Universitätsspital Basel, Basel.

PMID: 29461145
DOI: 10.1024/0040-5930/a000941

No abstract available

Publication types

Review

MeSH terms

Blood Glucose / metabolism
Blood Pressure / drug effects
Cardiovascular Diseases / blood*
Cardiovascular Diseases / prevention & control*
Diabetes Complications / blood*
Diabetes Complications / prevention & control*
Heart Failure / blood*
Heart Failure / prevention & control*
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Myocardium / metabolism
Natriuresis / drug effects
Risk Factors
Sodium-Glucose Transporter 1 / antagonists & inhibitors*

Substances

Blood Glucose
Hypoglycemic Agents
SLC5A1 protein, human
Sodium-Glucose Transporter 1